SCHEMBL7245763

SCHEMBL7245763

CCCC(C(N)=O)C(CC(C)C)C(=O)NC1CNC(=O)C2CCCN2C1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 13/20 0.47
▸ MMP1 P03956 5/20 0.47
▸ MMP3 P08254 4/20 0.47
▸ PSEN1 P49768 3/20 0.44
▸ PSEN2 P49810 3/20 0.44
▸ APH1B Q8WW43 3/20 0.44
▸ NCSTN Q92542 3/20 0.44
▸ APH1A Q96BI3 3/20 0.44
▸ PSENEN Q9NZ42 3/20 0.44
▸ NOTCH1 P46531 1/20 0.41
▸ RBPJ Q06330 1/20 0.41
▸ MMP2 P08253 2/20 0.39
▸ MMP7 P09237 2/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ MMP10 P09238 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ MMP14 P50281 1/20 0.38
▸ ADAM17 P78536 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7250598 0.91 MMP1 (0.48) APPMMP1MMP3PSEN1PSEN2
SCHEMBL7250754 0.87 MMP1 (0.47) APPMMP1MMP3PSEN1PSEN2
SCHEMBL7246490 0.75 APP (0.51) APPMMP1MMP3PSEN1PSEN2
SCHEMBL4498315 0.74 MMP1 (0.65) APPMMP1MMP3PSEN1PSEN2
SCHEMBL4492455 0.74 MMP1 (0.65) APPMMP1MMP3PSEN1PSEN2
SCHEMBL4498658 0.73 APP (0.63) APPMMP1MMP3PSEN1PSEN2
SCHEMBL4486169 0.73 APP (0.63) APPMMP1MMP3PSEN1PSEN2
SCHEMBL4471380 0.73 APP (0.64) APPMMP1MMP3PSEN1PSEN2
SCHEMBL4479697 0.73 MMP1 (0.64) APPMMP1MMP3PSEN1PSEN2
SCHEMBL4490159 0.72 APP (0.62) APPMMP1MMP3PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020055501-A1 Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-09 — — US claimed
US-6525044-B2 Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. BRISTOL-MYERS SQUIBB COMPANY 2003-02-25 — — US disclosed
EP-1261610-A2 SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-12-04 — — EP disclosed
US-20020055501-A1 Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-09 — — US disclosed
WO-2001060826-A2 SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055501-A1 Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production APP, APH1A, APH1B APP 1/4885MMP1 4233/4885MMP3 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback